权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Single application thixotropic antibiotic delivery systems for otitis externa

用于外耳炎的单次应用触变性抗生素输送系统

基本信息

批准号：
10251359
负责人：
Monica Andrea Serban
金额：
$ 69.61万
依托单位：
PROMILIAD BIOPHARMA, INC.
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10251359
关键词：
Affect Agreement Animal Model Anti-Bacterial Agents Antibiotic Resistance Antibiotics Award Bacterial Antibiotic Resistance Caregivers Characteristics Child Clinical Collaborations Data Dependence Development Doctor of Philosophy Dose Drops Drug Delivery Systems Ear Effectiveness Elderly Etiology Exhibits Formulation Funding Gel General Population Grant Growth Hand Head Health Health Care Costs Hydrogels Immunocompromised Host In Vitro Incidence Infection Intellectual Property Left Legal patent Life Liquid substance Malignant - descriptor Military Personnel Modeling Montana Nursing Homes Otitis Externa Pathology Patients Pharmaceutical Preparations Phase Physiological Population Pre-Clinical Model Prevention Prisons Process Production Pseudomonas aeruginosa Pseudomonas aeruginosa infection Readiness Recording of previous events Recurrence Reproducibility Request for Proposals Resistance development Risk Safety Schedule School Nursing Self Administration Site Staphylococcus aureus Swelling System Technology Technology Transfer Temperature Testing Time Tissues Topical Antibiotic Translating Treatment Protocols Tremor United States Universities Utah Work base biomaterial compatibility commercialization compliance behavior cost diabetic patient ear infection effective therapy experimental study in vivo insight multidisciplinary non-compliance novel older patient patient responsibilities point of care product development recurrent infection screening therapeutically effective

项目摘要

PROJECT SUMMARY Outer ear infections (otitis externa or OE) affect an estimated 10% of people in their lifetime, with associated healthcare costs amounting to over $500 million annually. The pathology is mostly treatable in the general population with topical antibiotics regimes, and can be supplemented in severe cases with systemic counterparts. However, incorrect application or non-compliance with administration schedule of antibiotics leads to infection persistence, recurrence and potentially, development of antibiotic resistant bacterial strains. In diabetic or elderly patients, the infection can be life threatening as it can progress into necrotizing or malignant otitis externa (MOE), with severe health consequences. In recent years, the incidence rate of MOE has seen a significant increase and has been associated with antibiotic resistant bacterial strains. Therefore, there is a critical need to develop safe and effective therapies for the treatment of OE and prevention of MOE. Our approach to this problem is the development of ThixOtic, a proprietary drug delivery system that would enable the one-time point-of-care application of drugs to effectively treat the infection and diminish treatment non-compliance related risk of antibiotic resistance development, infection recurrence and complications.

项目总结外耳感染(外耳炎或OE)在一生中影响大约10%的人，与医疗保健费用每年超过5亿美元。这种病理在一般情况下是可以治疗的。使用局部抗生素制度的人群，并可在严重情况下与全身对应人员进行补充。然而，抗生素的错误使用或不遵守给药程序会导致感染。抗生素耐药菌株的持久性、复发性和潜在的发展。在糖尿病或老年人中患者，感染可能危及生命，因为它可以发展为坏死性或恶性外耳炎(MOE)，会造成严重的健康后果。近年来，MOE的发病率呈显著上升趋势。并与抗药性细菌菌株有关。因此，迫切需要发展安全有效的治疗OE和预防MOE的方法。我们解决这个问题的方法是开发ThixOtic，这是一种专有药物输送系统，将使一次性护理点应用药物有效治疗感染，降低治疗不依从相关风险抗生素耐药性的产生、感染复发和并发症。